Atlas Trials

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Clinical trial NCT04514419 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04514419
Sponsor
BioRay Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2020-06-28
Primary completion
2024-09-11
Enrollment
408

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.